Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash from Financing Activities (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Cash from Financing Activities for 4 consecutive years, with $13.9 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Financing Activities fell 86.92% year-over-year to $13.9 million, compared with a TTM value of $42.0 million through Dec 2023, down 74.89%, and an annual FY2024 reading of $164.0 million, up 290.92% over the prior year.
  • Cash from Financing Activities was $13.9 million for Q4 2023 at Terns Pharmaceuticals, up from $20000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $135.2 million in Q1 2021 and bottomed at -$1.6 million in Q2 2021.
  • Average Cash from Financing Activities over 4 years is $28.6 million, with a median of $797000.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities tumbled 109.42% in 2021, then surged 662212.5% in 2022.
  • Year by year, Cash from Financing Activities stood at $68.6 million in 2020, then plummeted by 99.98% to $16000.0 in 2021, then soared by 662212.5% to $106.0 million in 2022, then tumbled by 86.92% to $13.9 million in 2023.
  • Business Quant data shows Cash from Financing Activities for TERN at $13.9 million in Q4 2023, $20000.0 in Q3 2023, and $489000.0 in Q2 2023.